Related references
Note: Only part of the references are listed.QuantiFERON TB Gold Testing for Tuberculosis Screening in an Inflammatory Bowel Disease Cohort in the United States
Bashar J. Qumseya et al.
INFLAMMATORY BOWEL DISEASES (2011)
Factors Impacting the Results of Interferon-gamma Release Assay and Tuberculin Skin Test in Routine Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Diseases
Pavol Papay et al.
INFLAMMATORY BOWEL DISEASES (2011)
Consensus Document on the Diagnosis, Treatment and Prevention of Tuberculosis
Julia Gonzalez-Martin et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2010)
Mucosal Healing and anti TNFs in IBD
Gert Assche et al.
CURRENT DRUG TARGETS (2010)
Interferon gamma release assays: principles and practice
Ajit Lalvani et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2010)
Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients
Luca Richeldi et al.
CHEST (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2009)
Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease
Alain M. Schoepfer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay
G. Matulis et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Screening for tuberculosis infection prior to initiation of anti-TNF therapy
Ajit Lalvani et al.
AUTOIMMUNITY REVIEWS (2008)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis:: a prospective study
G Ferrara et al.
LANCET (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
L Carmona et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report
JJ Gómez-Reino et al.
ARTHRITIS AND RHEUMATISM (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection
DR Roach et al.
JOURNAL OF IMMUNOLOGY (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
